Abstract:Background Clinical research showed that glucagon-like peptide-1 receptor (GLP1R) agonists (GLP1RA) reduced the incidence of major cardiovascular events in diabetic patients. The protective effect was more noteworthy in patients with established cardiovascular disease, associated with chronic low-grade inflammation resulting in endothelial dysfunction and arterial remodeling and fibrosis. Despite the clinically proven cardiovascular benefit of GLP1RA, the expression pattern of GLP1R and its function in the human vasculature remain poorly studied. Aim This study investigated the expression of GLP1R and its role in internal thoracic arteries (ITA) from patients with coronary artery disease. Methods Human ITA were collected from patients (N=30) undergoing coronary artery bypass surgery at the University Hospital of Strasbourg. Gene expression levels were assessed using RT-qPCR, protein levels by Western blot analysis, in situ tissue localization of proteins by immunofluorescence (IF) staining, and the level of oxidative stress using dihydroethidium. Results ITA showed a substantial difference in GLP1R mRNA levels reaching up to 7-fold among patients. GLP1R mRNA levels were positively correlated with those of SLC5A1, SLC5A2, F3, AT1R, IL1B, IL6, TNFα, VCAM1 and NCF1, and negatively with NOS3 mRNA levels. High GLP1R expressing ITA showed high levels of phosphorylated p65 NF-κB, cell adhesion molecule VCAM1, members of the angiotensin system (ACE1 and AT1R), remodeling and fibrotic markers (MMP9, MMP2, TGFβ) and a low level of eNOS, whereas the contrary was observed for low GLP1R expressing ITA. IF staining showed that GLP1R signals were predominantly observed in the endothelium of low GLP1R expressing ITA and in the vascular smooth muscle of high GLP1R expressing ITA. Prominent CD68 staining associated with the endothelium and the perivascular adipose tissue were observed in high but not low GLP1R expressing ITA. High GLP1R expressing ITA showed increased levels of oxidative stress, which were inhibited by the antioxidant N-acetylcysteine (NAC), NADPH oxidase inhibitor (VAS-2870), ACE inhibitor (perindoprilat), AT1R antagonist (losartan), TNF-α receptor neutralizing antibody (infliximab), selective SGLT2 inhibitor (empagliflozin), dual SGLT1/2 inhibitor (sotagliflozin) and by GLP1R agonists (liraglutide and semaglutide) with inhibitory effects amounting to about 50 to 75%. Conclusion These findings indicate that GLP1R expression levels in human ITA are dependent on low-grade inflammation and linked to endothelial dysfunction, pro-thrombotic, pro-remodeling and pro-fibrotic responses. Furthermore, they were associated with increased level of oxidative stress sensitive to inhibitors of either the local angiotensin system, SGLT2, TNFα and agonists of GLP1R. Thus, the cardiovascular beneficial effects of GLP1R agonists might be attributable to their ability to reduce the pro-oxidant stimulatory signal related to low-grade inflammation. Funding Acknowledgement Type of funding sources: Other. Main funding source(s): Frency Society of Vascular Medicine (SFMV)

GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways

A Novel Angiogenesis Role of GLP-1(32-36) to Rescue Diabetic Ischemic Lower Limbs Via GLP-1R-Dependent Glycolysis

Novel Angiogenesis Role of GLP-1(32–36) to Rescue Diabetic Ischemic Lower Limbs via GLP-1R–Dependent Glycolysis in Mice

882-P: A Novel Angiogenesis Role of GLP-1(32-36) to Rescue Diabetic Ischemic Lower Limbs Via GLP-1R–Dependent Glycolysis

Rosiglitazone Via Upregulation of Akt/Enos Pathways Attenuates Dysfunction of Endothelial Progenitor Cells, Induced by Advanced Glycation End Products

Liraglutide Prevents High Glucose Induced HUVECs Dysfunction Via Inhibition of PINK1/Parkin-dependent Mitophagy

GLP-1 Inhibits High-Glucose-Induced Oxidative Injury of Vascular Endothelial Cells

Dapagliflozin Improves Angiogenesis after Hindlimb Ischemia through the PI3K-Akt-eNOS Pathway

Exenatide Exerts Direct Protective Effects on Endothelial Cells Through the AMPK/Akt/eNOS Pathway in a GLP-1 Receptor-Dependent Manner.

GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage

Glucagon-Like Peptide-1 Protects Against Cardiac Microvascular Injury In Diabetes Via A Camp/Pka/Rho-Dependent Mechanism

Liraglutide restores angiogenesis in palmitate-impaired human endothelial cells through PI3K/Akt-Foxo1-GTPCH1 pathway

Glucagon-Like Peptide 1 Protects against Hyperglycemic-Induced Endothelial-to-Mesenchymal Transition and Improves Myocardial Dysfunction by Suppressing Poly(ADP-Ribose) Polymerase 1 Activity

Db121025 1697..1708

Association of Placental Growth Factor and Angiopoietin in Human Retinal Endothelial Cell-Pericyte co-Cultures and iPSC-Derived Vascular Organoids

Direct Effects of Glucagon-Like Peptide-1 on Myocardial Contractility and Glucose Uptake in Normal and Postischemic Isolated Rat Hearts.

The ghrelin gene products and exendin-4 promote survival of human pancreatic islet endothelial cells in hyperglycaemic conditions, through phosphoinositide 3-kinase/Akt, extracellular signal-related kinase (ERK)1/2 and cAMP/protein kinase A (PKA) signalling pathways

GLP-1 receptor expression in human internal thoracic arteries is dependent on low-grade inflammation potentially explaining the cardiovascular protective effect of GLP1-R agonists

Sodium-glucose cotransporter 1 promotes the biofunctions of perivascular preadipocytes mediated by Akt/mTOR/p70S6K signaling pathway

Apelin prevents diabetes-induced poor collateral vessel formation and blood flow reperfusion in ischemic limb

High-glucose Induced HIF-1α Down-Regulation Impairs the Function of the Endothelial Progenitor Cells Via PI3K/AKT Signaling Pathway